Canada - English - Health Canada

mantra pharma inc - perindopril erbumine - tablet - 8mg - perindopril erbumine 8mg - angiotensin-converting enzyme inhibitors

Canada - English - Health Canada

nora pharma inc - perindopril erbumine - tablet - 8mg - perindopril erbumine 8mg - angiotensin-converting enzyme inhibitors

Canada - English - Health Canada

pro doc limitee - perindopril erbumine; indapamide - tablet - 8mg; 2.5mg - perindopril erbumine 8mg; indapamide 2.5mg

Canada - English - Health Canada

sivem pharmaceuticals ulc - perindopril erbumine - tablet - 8mg - perindopril erbumine 8mg - angiotensin-converting enzyme inhibitors

Canada - English - Health Canada

sanis health inc - perindopril erbumine - tablet - 8mg - perindopril erbumine 8mg - angiotensin-converting enzyme inhibitors

Canada - English - Health Canada

pro doc limitee - perindopril erbumine - tablet - 8mg - perindopril erbumine 8mg - angiotensin-converting enzyme inhibitors

Canada - English - Health Canada

mylan pharmaceuticals ulc - perindopril erbumine - tablet - 8mg - perindopril erbumine 8mg - angiotensin-converting enzyme inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; hydrophobic colloidal silica anhydrous; chlorophyllin-copper complex aluminium lake - indosyl mono is indicated for: the treatment of hypertension; indosyl mono is indicated for: the treatment of heart failure. in such patients it is recommended that indosyl mono be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of indosyl mono has not been demonstrated for new york heart association category iv patients) indosyl mono is indicated for: patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: hydrophobic colloidal silica anhydrous; magnesium stearate; chlorophyllin-copper complex; lactose monohydrate; microcrystalline cellulose - treatment of hypertension. treatment of heart failure. in such patients it is recommended that perindo be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindo has not been demonstrated for new york heart association category iv patients). patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - perindopril erbumine -